Indication

For the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

Medicine details

Medicine name:
zanubrutinib (Brukinsa)
SMC ID:
SMC2452
Pharmaceutical company
BeiGene UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
02 May 2022